NeurologyLive® Friday 5 — July 11, 2025

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: How Phase 3 TEMPLE Results Support CGRP Inhibitors as First-Line Preventives for Migraine: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center explained why data from trials like TEMPLE help strengthen the argument for CGRP therapies as first-line treatments for migraine. [WATCH TIME: 3 minutes]

2: Advancing Research and Drug Development for Isolated RBD: Emmanuel During, MD

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai detailed how monitoring tools and neuroprotective approaches are evolving for iRBD as research intensifies on its link to Parkinsonian syndromes. [WATCH TIME: 4 minutes]

3: Why Early Identification of Atypical Parkinsonian Syndromes Matters in the Clinic: David Shprecher, DO, MSci, FAAN

The director of movement disorders at the Banner Sun Health Research Institute discussed distinguishing atypical Parkinsonian disorders early and planning care around their complex symptomatology. [WATCH TIME: 4 minutes]

4: NeuroVoices: Kumar Budur, MD, MS, on BP1.15205 as a Next-Gen Therapy for Narcolepsy

The chief medical officer and scientific officer at Harmony Biosciences discussed the pharmacologic rationale and preclinical development of BP1.15205, a novel orexin receptor agonist for hypersomnolence.

5: Oscillations in Non-REM Sleep Offer New Insight Into Alzheimer Disease Biology: Bryce Mander, PhD

The associate professor of psychiatry and human behavior at UC Irvine explored how analyzing specific sleep oscillations may uncover early neurodegenerative changes and guide future therapeutic targets. [WATCH TIME: 4 minutes]